Oncogenic role of LncRNA DLEU2 in thyroid cancer through a NAT10/USP39 regulatory axis
Mammalian Genome · 2026
DOI: 10.1007/s00335-026-10225-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mammalian Genome, 2026. Verfasst von Jiwen Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, C…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Thyroid Neoplasms, N-Terminal Acetyltransferase E, Ubiquitin-Specific Proteases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Natural Science Research Project of Anhui Provincial Department of Education, Health research project of Anhui Province, Key Scientific Research Fund Project of Wannan Medical College.
Abstract (Originalsprache)
Thyroid cancer incidence is rapidly increasing worldwide, with many patients’ developing radioiodine-refractory disease that leads to a poor prognosis. Long non-coding RNAs (lncRNAs) are critical regulators of tumor progression. While DLEU2 has been implicated in several cancers, its specific function in thyroid cancer remained undefined. This study aimed to investigate the role of DLEU2 in thyroid cancer progression through its interaction with NAT10 and USP39. We examined DLEU2 expression in 70 paired thyroid cancer and adjacent tissues, and in multiple cell lines using qRT-PCR, finding marked upregulation correlated with higher pathological grade and worse survival. Functional assays demonstrated that silencing DLEU2 significantly reduced cell proliferation, migration, and invasion in vitro, while its overexpression produced the opposite effects. Mechanistically, co-immunoprecipitation confirmed that DLEU2 physically interacts with both NAT10 and USP39, and DLEU2 knockdown specifically decreased their protein levels without affecting mRNA expression, suggesting post-translational regulation. These in vitro findings were further validated in vivo, where tumors from DLEU2-silenced xenografts exhibited significantly smaller volume and weight, accompanied by reduced Ki-67 expression. Overall, this study identifies DLEU2 as an oncogenic lncRNA that promotes thyroid cancer progression through stabilization of NAT10 and USP39, highlighting its potential as both a promising biomarker and therapeutic target for clinical intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China.
- Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institutes, Wannan Medical College, Wuhu, Anhui, China.
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China.
- Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institutes, Wannan Medical College, Wuhu, Anhui, China. tianfang.5000@aliyun.com.
- Department of Thyroid and Breast Surgery, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), No. 2, Zheshan West Road, Jinghu District, Wuhu, 241001, Anhui, China. tia…
- Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Wannan Medical College, Wuhu, 241002, Anhui, China. silently00@sina.com.
ORCID-Profile: Zhiyong Zhao
Förderung
- Natural Science Research Project of Anhui Provincial Department of Education
- Health research project of Anhui Province
- Key Scientific Research Fund Project of Wannan Medical College
- Climbing Scientific Peak Project for Talents, The Second Affiliated Hospital of Wannan Medical College
Zitieren
APA
Yang, J., Li, C., Yin, W., Fang, F., & Zhao, Z. (2026). Oncogenic role of LncRNA DLEU2 in thyroid cancer through a NAT10/USP39 regulatory axis. Mammalian Genome. https://doi.org/10.1007/s00335-026-10225-4
Vancouver
Yang J, Li C, Yin W, Fang F, Zhao Z. Oncogenic role of LncRNA DLEU2 in thyroid cancer through a NAT10/USP39 regulatory axis. Mammalian Genome. 2026. doi:10.1007/s00335-026-10225-4
BibTeX
@article{Yang2026,
author = {Yang, Jiwen and Li, Cheng and Yin, Weili and Fang, Fang and Zhao, Zhiyong},
title = {Oncogenic role of LncRNA DLEU2 in thyroid cancer through a NAT10/USP39 regulatory axis},
journal = {Mammalian Genome},
year = {2026},
doi = {10.1007/s00335-026-10225-4}
}
EUVIMED